Equity News

Micron is seen as a key beneficiary of robust memory chip demand from the AI data center buildout.

The travel company expects 2026 revenue of between $15.6 billion and $16 billion.

Earlier, reports said OpenAI missed several internal targets for 2026 even as Anthropic’s revenue surged.

TD Cowen and Baird lowered McDonald’s price targets following the first-quarter earnings.

For Nvidia, it is only the latest investment-and-commercial partnership deal, similar to those it has struck with CoreWeave, Nebius and others.

Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ this week.

Brent crude futures expiring in July were up about 0.44% at the time of writing, while WTI crude futures expiring in June were up about 0.15%.

One influencer warned that shareholders could face “permanent economic leakage” if Tesla ends up paying SpaceXAI for AI services.

Innodata increased its full-year 2026 revenue growth forecast to around 40% or more.

The rivalry between Anthropic and OpenAI, both targeting an IPO this year, is at a fever pitch.

Traders are also watching the FDA review of ImmunityBio’s resubmitted Anktiva plus BCG filing for non-muscle invasive bladder cancer with papillary tumors.

Nvidia’s China sales have effectively dropped to zero amid U.S. export restrictions, with no clear path forward yet emerging.

A hantavirus outbreak aboard a cruise ship has resulted in three deaths and raised global health concerns.

BRC Group Holdings reported first-quarter earnings results on Thursday, posting an increase of 89% in revenue, driven partly by its investment in SpaceX.

Inovio is the most direct hantavirus play based on earlier DNA vaccine studies targeting Andes, Hantaan, and Puumala strains.

Datadog is also on track to be the top gainer this week on the Nasdaq 100 and the second-best performer on the S&P 500.

The company forecast Q2 revenue of at least $750 million, below analyst estimates of $770.41 million.

Apple, Micron Technology, and Qualcomm stocks climbed to 52-week highs on Thursday amid strong AI-driven demand and Wall Street optimism.

NuScale Power reported first-quarter revenue of $0.57 million, 96% lower than the revenue reported in the corresponding quarter of 2025.

Wall Street expects another loss-making quarter, with Koyfin estimates projecting EPS loss to widen to $0.06 from $0.05.

Weak earnings, lower outlooks, and rising costs show middle-class consumers are spending less on food and fitness services broadly.

The latest move by Amazon adds pressure on Hims, which already offers branded GLP-1 drugs including Wegovy, Ozempic and Zepbound.

Opendoor said second-quarter revenue will rise 25% sequentially and that it expects to generate positive adjusted EBITDA.

U.S. President Donald Trump has reportedly reiterated that the ceasefire with Iran still holds, despite renewed tensions in the Strait of Hormuz.

Capricor is seeking court approval to pursue an alternative commercialization path for Deramiocel and wants parts of the agreement terminated.

Under the deal, NVIDIA will receive a five-year warrant to purchase up to 30 million IREN shares at $70 per share, while IREN will deploy massive clusters of NVIDIA’s latest GPUs.

Lyft reported mixed first-quarter results and clocked double-digit growth in revenue while net income fell below estimates.

Weaker crypto markets dragged down Coinbase’s core trading business.

SoundHound AI’s Q1 revenue jumps 52%, beating expectations.

Cloudflare laid off one-fifth of its total employees amid a shift to an agentic AI operating model.

Rocket Lab said that a confidential customer booked five dedicated missions on its Neutron rocket and three dedicated missions on its small -sat Electron rocket, spanning 2026–2029.

Gilead slashed its full-year earnings outlook primarily due to anticipated charges and financing costs from its recent acquisitions of Arcellx, Ouro Medicines, and Tubulis.

Broadcom’s ambition to develop custom chips with OpenAI hits an $18 billion financing roadblock.

According to a Reuters report, citing data from the China Passenger Car Association, sales of the vehicle built at Tesla’s gigafactory in China totaled 79,478 in April.

Reuters reported on the sale plans on Thursday, citing people familiar with the matter.

QCOM CEO hinted at working on top-secret hardware with “pretty much all” major AI players earlier this week.

Following Uber’s solid Q1 results and upbeat Q2 guidance, several top analysts raised their price targets on the ride-hailing and delivery giant, citing accelerating demand in Mobility and Delivery, margin expansion, and robust share buybacks.

During the first quarter, Iovance posted a 45% increase in revenue to $71.4 million, which came in below Wall Street’s estimates of $75.6 million, according to Fiscal.ai data.

The company is confident about its growth prospects for the rest of the year and has provided an upbeat forecast.

Citadel and its CEO, Kenneth Griffin, have both bought into GLND stock, per SEC filings.

AppLovin expects higher advertising revenue going forward as it expands its Axon platform globally.

Fastly shares continued their downward trajectory after reporting first-quarter results that were only slightly ahead of expectations.

The Boeing CEO is reportedly joining Trump on his China visit next week, in hopes of returning with new orders for the company, which had been out of the Chinese market in recent years.

Kala Bio said it will implement a 1-for-50 reverse stock split, effective after the closing bell on May 8.

Rackspace Technology inked a multiyear AI partnership with AMD to develop a new category called ‘governed enterprise AI infrastructure.’

During an interview with CNBC, Jones reflected on the launches of the personal computer and the internet, saying both sparked productivity booms that lasted roughly four to five-and-a-half years.

The company saw strong sales in its top operating markets, driven by its competitive pricing advantage.

Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

ZenaTech stated that the acquisition of the Australian land surveying and spatial services firm aligns with its long-term vision of building a scalable AI autonomy platform through Drone-as-a-Service.